West Nile virus neuroinvasive disease associated with rituximab therapy

[1]  B. Sander,et al.  Epidemiologic and clinical parameters of West Nile virus infections in humans: a scoping review , 2017, BMC Infectious Diseases.

[2]  J. Carey,et al.  Seronegative West Nile Virus Infection in a Patient Treated with Rituximab for Rheumatoid Arthritis. , 2017, American Journal of Medicine.

[3]  M. Rosenblum,et al.  West Nile Virus Central Nervous System Infection in Patients Treated With Rituximab: Implications for Diagnosis and Prognosis, With a Review of Literature , 2015, Open forum infectious diseases.

[4]  D. Karussis,et al.  Delayed-onset flaccid paralysis related to west Nile virus reactivation following treatment with rituximab: a case report , 2014, BMC Research Notes.

[5]  Kavita K. Trivedi,et al.  Donor-derived West Nile virus infection in solid organ transplant recipients: report of four additional cases and review of clinical, diagnostic, and therapeutic features. , 2014, Transplantation.

[6]  A. Brault,et al.  West Nile virus: review of the literature. , 2013, JAMA.

[7]  K. Tyler,et al.  Impact of rituximab‐associated B‐cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients , 2010, Clinical transplantation.

[8]  S. Staugaitis,et al.  Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma. , 2005, Clinical lymphoma & myeloma.

[9]  N. Khardori,et al.  Transient parkinsonism in West Nile virus encephalitis. , 2003, The American journal of medicine.

[10]  C. Litwin,et al.  Detection of IgG and IgM to West Nile virus. Development of an immunofluorescence assay. , 2003, American journal of clinical pathology.

[11]  M. Dupuis,et al.  First Isolation of West Nile virus from a Patient with Encephalitis in the United States , 2002, Emerging infectious diseases.

[12]  A. Papa,et al.  West Nile virus IgM and IgG antibodies three years post- infection. , 2015, Hippokratia.